News for Providers
Top stories summarized by our editors
7/20/2018

Researchers used a cohort of 3,549 patients with type 2 diabetes and found an increased risk for hypoglycemic events when titration with insulin glargine 100 U/mL was added to sulfonylurea in patients with low body mass index or low levels of fasting C-peptide, prior to starting basal insulin. The findings, published in Diabetes, Obesity and Metabolism, showed that "people with greater insulin resistance may benefit from the addition of [glargine 100 U/mL] to an oral regimen consisting of metformin, while avoiding sulfonylurea-based regimens and/or withdrawing sulfonylurea when basal insulin is initiated."

Full Story:
Endocrinology Advisor
More Summaries:
insulin glargine, diabetes, metformin
7/20/2018

A study in Diabetes Care showed that patients with type 2 diabetes and severe hypoglycemia had similar average A1C levels and had a prior diagnosis of non-severe hypoglycemia, compared with those who did not experience severe hypoglycemia. Researchers analyzed 50,439 patients from the Cleveland Clinic Health System and found an association between an increased risk for severe hypoglycemia and A1C level of less than 6%, insulin, increased number of diabetes medications, sulfonylureas, increased Charlson comorbidity index and black race.

7/20/2018

Researchers found that the Ten Questions screening tool yielded 100% sensitivity and 51.2% specificity in identifying serious disability among children who were HIV-positive, compared with 90.2% sensitivity and 63.9% specificity for children who were HIV-negative. The study of children in South Africa was reported in PLOS ONE.

More Summaries:
HIV-positive
7/20/2018

Researchers found an harmful association between higher HDL cholesterol levels and atherosclerosis risk among women at least 10 years into postmenopause and those whose age was greater at menopause. The findings in Arteriosclerosis, Thrombosis, and Vascular Biology, based on data for 1,138 women ages 45 to 84, showed that large HDL particles correlated with an increased risk for cardiovascular disease near menopause, but the good qualities of HDL may return as women move further away from menopause.

More Summaries:
postmenopause
7/20/2018

Louisiana is one of the most economically challenged states in the US but it could become a model in the future for hepatitis C elimination as state officials are working out a deal with Gilead Sciences to change how it pays for those medications for the benefit of the 34,600 people who are not receiving treatment for HCV. State Health Secretary Rebekah Gee has been in talks with Gilead officials to develop what they describe as a subscription model wherein Louisiana would pay a fixed sum over a period of several years while Gilead would supply the state's medication requirements.

Full Story:
National Public Radio
More Summaries:
Gilead Sciences, HCV
7/20/2018

SNMMI and other radiology associations, radiopharmaceutical vendors, patient groups and medical imaging companies sent a letter urging the Senate and House subcommittees on energy and water development to designate $20 million to supporting molybdenum-99 production in the US. Despite the American Medical Isotopes Production Act of 2012, domestic Mo-99 supply continues to be inadequate, the groups wrote.

More Summaries:
SNMMI
7/20/2018

Patients with breast, colon, lung or prostate cancer who received complementary therapies, such as traditional Chinese medicine, homeopathy, herbs or naturopathy, had a higher mortality risk, compared with those who only received chemotherapy, radiation or surgery, Yale University researchers reported in JAMA Oncology. The findings also showed an increased likelihood of refusing standard treatment among those who used complementary medicine, but CM was not tied to higher mortality risk after adjusting for treatment delays and refusal of conventional treatment.

Full Story:
HealthDay News
7/20/2018

The FDA put on partial hold an early-stage study for Mersana Therapeutics' XMT-1522, being assessed to treat patients with advanced HER2-expressing cancers of the breast, lung and stomach. The decision followed a patient death potentially linked to receiving the drug.

Full Story:
Reuters
More Summaries:
FDA, Mersana Therapeutics, cancer, Mersana
7/20/2018

A Clarivate Analytics report showed that the impact factor of SNMMI's Journal of Nuclear Medicine increased from 6.646 in 2016 to 7.439 in 2017, making it the fifth highest ranked medical imaging journal. "Among nuclear medicine journals, JNM continues to have the highest number of citations, the highest average five-year impact factor, the highest number of citable articles, and the highest influence score," said JNM Editor-in-Chief Dr. Johannes Czernin.

Full Story:
Radiology Business
7/20/2018

Los Angeles officials were surprised by a 22% increase this year in the over-62 population of homeless people -- an exception to the overall slight drop in homelessness. Rising housing costs and medical costs have been cited as driving factors for the trend.